Diabetes Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Diabetes Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Drug Development
Biotech president looks forward to cash flow from diabetes drug
September 27th, 2004
Robert Rieveley, the president of Biotech Holdings said in a quarterly report to shareholders that the launch of the company's Sucanon diabetes drug will put the company into a cash flow position. "I am pleased to report that report that, with the coming launch of Sucanon in Mexico, followed by launch in Peru, we can look forward to the beginning of cash flow from our investment in this important new drug," said Robert Rieveley, the president of Biotech. "Production, tableting and quality-control processes for Sucanon are now fully operational and sales of Sucanon are planned to begin at the end of the current quarter, with revenues beginning in the...
Source: Diabetes Week (2004-09-27)
|
